For Healthcare Professionals

Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes

clipboard-pencil

About the study

SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to evaluate the efficacy and safety of SP2086 as monotherapy in patients with Type 2 Diabetes Mellitus in Metformin monotherapy Who Have Inadequate Glycemic Control treated with diet and exercise for 3 months
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Patients diagnosed with type 2 diabetes mellitus
  2. Patients have treated with diet/exercise at least 3 months
  3. 7.5% ≤HbA1C ≤11.0% at screening,7.0% ≤HbA1C ≤10.5% after run-in

EXCLUSION CRITERIA

  1. Patient has history of type 1 diabetes mellitus
  2. Patient has history of ketoacidosis
  3. Patient has history of severe unconscious hypoglycemosis
  4. Patient has history of acute and chronic pancreatitis or pancreatic injury that may lead to high risk of pancreatitis
  5. Patient has history of decompensated heart failure (NYHA class III and IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, persistence and clinical
  6. Patient has history of a history of hypertension, and after antihypertensive treatment, systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg
  7. Patient has severe liver or kidney disease,alanine aminotransferase >2×UNL, Aspartate Aminotransferase >2×upper normal limit(UNL);total bilirubin >2×UNL; creatinine>1.5 mg/dL (Male,132.6μmol/L) ,>1.4 mg/dL(Female,123.8μmol/L)
  8. Patient has severe chronic gastrointestinal disease or therapy that may affect drug absorption, such as gastrointestinal surgery
  9. Patient has severe haematological diseases or other diseases leading to hemolyze and red blood cell unstable (malaria、haemolytic anaemia eg. )
  10. Patient has other endocrine diseases, for example hyperthyroidism、hypothyroidism、hypercortisolism、multiple endocrine neoplasia and so on
  11. Patient has history of malignancy
  12. Patient has history of alcohol or drug abuse
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 86 10 66887329Email iconEmail Study Center

Study’s details


Contition

Type 2 Diabetes

Age

18+

Phase

Phase 3

Participants needed

450

Est. Completion Date

Jan 2015

Treatment type

Interventional


Sponsor

Jiangsu HengRui Medicine Co., Ltd.

ClinicalTrials.gov identifier

NCT01970033

Study number

HR-SP2086-301

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.